160969-12-0

Upstream product

• 161024-53-9 (R)-(-)-1-acetyl-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carbonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 175837-07-7 1-acetyl-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carbonitrile 
• 175837-01-1 1-acetyl-5-(2-aminopropyl)-2,3-dihydro-1H-indole-7-carbonitrile 
• 160969-03-9 1-(2-methanesulfonyloxyethoxy)-2-(2,2,2-trifluoroethoxy)benzene 

Downstream Products

• 160969-20-0 tert-butyl [(2R)-1-(7-cyanoindolin-5-yl)propan-2-yl]-{2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}carbamate 
• 1423218-40-9 tert-butyl (2R)-(1-(1-(3-benzyloxypropyl)-7-cyanoindolin-5-yl)propane-2-yl)-N-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 1427271-99-5 (R)-tert-butyl(1-(7-cyano-1-(3-hydroxypropyl)indolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 885340-13-6 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carbonitrile 
• 1427272-02-3 (R)-tert-butyl(1-(1-allyl-7-cyanoindolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 160970-54-7 silodosin 

Relevant academic research and scientific papers

Enantioselective synthesis of (-)-(R) Silodosin by ultrasound-assisted diastereomeric crystallization

Enantioselective synthesis of clinically approved drug - Silodosin for the treatment of benign prostatic hyperplasia from the commercially available compounds 1-acetyl-5-(2-aminopropyl) indoline-7-carbonitrile A and 2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl methanesulfonate C is explored. Key step in the synthesis is chiral resolution of intermediate 1, which was achieved by a simple diastereomeric crystallization using (S)-(+)-mandelic acid assisted by ultrasonication. The present synthetic strategy has lesser number of steps and is vastly improved the overall yield in this short route towards target compound - Silodosin.

PROCESS FOR THE PREPARATION OF SILODOSIN

The invention relates to a process for preparing silodosin. The invention relates to the preparation of substantially pure silodosin. The invention also relates to silodosin solid particles, wherein 90 volume-percent of the particles (D90) are less than 10 microns and a process for achieving the particle size (D90) less than 10 microns. The invention also relates to pharmaceutical compositions of silodosin comprising 90 volume-percent of the particles (D90) less than 10 microns.